Compare BTBT & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | DRTS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 125 |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 546.5M |
| IPO Year | 2017 | N/A |
| Metric | BTBT | DRTS |
|---|---|---|
| Price | $1.62 | $7.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 19.4M | 266.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 218.75 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $108,050,720.00 | N/A |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $90.95 | $1,055.39 |
| P/E Ratio | $3.52 | ★ N/A |
| Revenue Growth | ★ 140.56 | N/A |
| 52 Week Low | $1.49 | $2.30 |
| 52 Week High | $4.55 | $8.60 |
| Indicator | BTBT | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 50.48 |
| Support Level | $1.53 | $6.51 |
| Resistance Level | $2.43 | $7.77 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 10.94 | 36.30 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.